- $1.46bn
- $654.34m
- $266.72m
- 47
- 21
- 16
- 17
Annual balance sheet for Zai Lab, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 276 | 1,187 | 1,409 | 1,008 | 806 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3.79 | 5.17 | 54.8 | 48.6 | 65.3 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 292 | 1,216 | 1,501 | 1,124 | 940 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 36.4 | 46.9 | 57.3 | 77.4 | 68.6 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 355 | 1,298 | 1,610 | 1,220 | 1,036 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 46.6 | 98 | 193 | 140 | 203 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 60.5 | 128 | 230 | 175 | 240 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 295 | 1,169 | 1,380 | 1,046 | 796 |
| Total Liabilities & Shareholders' Equity | 355 | 1,298 | 1,610 | 1,220 | 1,036 |
| Total Common Shares Outstanding |